Narmac,

You are anchoring your expectations to a very early statement in Nov 2014 of a clinical trial whose design was not yet finalized or approved. For example, it was going to be a Phase 2/3, then it became a Phase 3. It was going to be only rosuvastatin, then it became both atorvastatin and rosuvastatin. I don't even know if it was named BETonMACE yet in 2014. Even if it was, I would argue that the trial design changed so much between 2014 and 2015 that it isn't even fair to call the 2014 version BETonMACE. It is also unfair to apply a 2.5 year trial duration statement from Sept/Oct 2015 to a statement made nearly a year earlier about a trial whose design eventually changed. 

BearDownAZ